News

Maj Institute of Pharmacology Polish Academy of Sciences is a consortium member of the GRIEG research project Maj Institute of Pharmacology Polish Academy of Sciences is a consortium member of the GRIEG research project Maj Institute of Pharmacology Polish Academy of Sciences is a consortium member of the GRIEG research project entitled „Theranostic nanocarriers for drug delivery in central nervous system disorders” funded under the Norwegian Financial Mechanism 2014 – 2021. Prof. Piotr Warszyński from Jerzy Haber Institute of Catalysis and Surface Chemistry PAS is the leader of the project. Apart from IP PAS (Department of Experimental Neuroendocrinology, WP leader Prof. Władysław Lasoń)), other project partners include The Henryk Niewodniczański Institute of Nuclear Physics PAS,  SINTEF AS (Trondheim) and  Oslo University Hospital. The main project objective is to develop a new strategy to deliver neuroprotectants by applying biocompatible theranostic nanocarriers, traceable in vivo by MRI, which can cross the blood-brain barrier without imposing side effects on its normal function. Application of such neuroprotective nanocarriers can be the solution for future therapies of stroke and neurodegenerations like Alzheimer's and Parkinson's diseases.
PASIFIC Call 1 PASIFIC Call 1 Maj Institute of Pharmacology Polish Academy of Sciences (IP PAS) has become Host Institute for the realization of the Postdoctoral Fellowship of Dr. Rugmani Meenambal (India), the winner of the first Call of the PASIFIC Programme, which is co-financed from the Horizon 2020 programme in the frame of Marie Skłodowska-Curie Actions Co-funding of regional, national and international programmes (MSCA COFUND). During 2-year postdoctoral fellowship, the laureate will be running the interdisciplinary project “Neuroprotective properties of theranostic lanthanide oxides nanoparticles against neurotoxin-induced cellular models of Parkinson’s disease” (acronym TheraLanOx). The research will be conducted in the Department of Experimental Neuroendocrinology IP PAS and in the Jerzy Haber Institute of Catalysis and Surface Chemistry Polish Academy of Sciences (ICSC PAS, Supporting Institute) under the scientific supervision of Dr. Danuta Jantas (Applicant’s Supervisor, IP PAS) and Prof. Piotr Warszyński (Applicant’s Supporting Supervisor, ICSC PAS).
Miniatura 5 results Miniatura 5 results Dr. Natalia Malikowska-Racia has been awarded a grant from the National Science Centre (NCN) MINIATURA 5 for a project: "Pharmacotherapy of apathy and motivation disorders: studying the effects of chronic naltrexone treatment on motivation in rats". Apathy manifests as a lack of motivation and decreased activity that may contribute to depressive disorders. Nowadays, the effective and safe pharmacotherapy of motivation disorders is unavailable, yet some observations suggest that treatment with naltrexone may benefit apathy. Research indicates that this phenomenon involves mechanisms different than opioid receptors antagonism that underlies the clinical use of naltrexone in addictions therapy. The study “Pharmacotherapy of apathy and motivation disorders: studying the effects of chronic naltrexone treatment on motivation in rats” aims to evaluate the potential effect of chronic treatment with naltrexone on motivation in rats and determine possible protein pathways underlying driving this effect. Congratulations! 
Miniatura 5 results Miniatura 5 results Dr Katarzyna Rafa-Zabłocka has been awarded a grant from the National Science Centre (NCN) MINIATURA 5 for a project entitled: “Exploiting of CRISPR/Cas9 gene-editing tool for the engineering of models with selective double deletion CREB/CREM in chosen brain structure.” Studies involving CREB deficient animals often neglected increase in expression of CREM protein induced by the lack of CREB, which phenomenon could have been partly responsible for unexpected results of these experiments. The new model proposed in the MINIATURA project by utilizing CRISPR/Cas9 system will enable selective and simultaneous deletion of both genes CREB and CREM in a chosen brain structure. Animals with CREB/CREM deletion may become a new tool in studies on CREB function not only in the pathogenesis of depression, but also in drug addiction, anxiety, learning and memory etc. Congratulations!